Results 31 to 40 of about 13,103,023 (178)

Lower Serum HBV RNA Level is Associated with Liver Cirrhosis in Patients Treated with Nucleos(t)ide Analogs: A Population-Based Cross-Sectional Study. [PDF]

open access: yesTurk J Gastroenterol
Background/Aims: There is evidence suggesting an association between hepatitis B virus (HBV) RNA and hepatic fibrosis in treatment naïve chronic hepatitis B (CHB) patients.
Wu J   +6 more
europepmc   +2 more sources

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years. [PDF]

open access: yesJ Gastroenterol
Hosaka T., Hikita H., Tahata Y., et al. On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.
Hosaka T   +28 more
europepmc   +2 more sources

The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. [PDF]

open access: yesFront Public Health, 2021
Background and Aim: Although most chronic hepatitis B (CHB) patients achieve effective virological suppression after receiving long-term nucleos(t)ide analogs (Nucs) therapy, the safety of off-therapy is controversial under the monitor.Methods: We ...
Wang M   +7 more
europepmc   +2 more sources

Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy. [PDF]

open access: yesBMC Pregnancy Childbirth, 2021
Background We encourage Hepatitis B virus-infected mothers to breastfeed postpartum, even when continuing pregnancy category B nucleos(t)ide analogs (NAs) treatment.
Li EM   +6 more
europepmc   +2 more sources

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. [PDF]

open access: yesJ Clin Transl Hepatol, 2014
Infection with hepatitis B virus (HBV) is a worldwide health problem. Chronic hepatitis B can lead to fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC). Management of the latter two conditions often requires liver transplantation. Treatment with conventional interferon or pegylated interferon alpha can clear the virus, but the rates are ...
Gupta N, Goyal M, Wu CH, Wu GY.
europepmc   +4 more sources

Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.

open access: yesPLoS ONE, 2022
Nucleos(t)ide analogs are standard-of-care for the treatment of chronic hepatitis B and can effectively reduce hepatitis B virus (HBV) replication but rarely leads to cure.
Dara L Burdette   +7 more
doaj   +1 more source

Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia. [PDF]

open access: yesFront Med (Lausanne)
IntroductionLow-level viremia (LLV) is associated with the progression of liver fibrosis and a high risk of hepatocellular carcinoma in patients with chronic hepatitis B (CHB). The present study aimed to compare the efficacy between nucleos(t)ide analogs
Wang L   +6 more
europepmc   +2 more sources

Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss. [PDF]

open access: yesVirol J
Background/Aims It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy.
Gao N   +9 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy